Cardiol Therapeutics Inc. (CRDL)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$1.32−6.38%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $160M
- 52-week range
- $0.88 – $2.34
- 52-week change
- +30.56%
- EPS (trailing)
- −$0.25
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 12, 2026
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Headquarters: Oakville, Canada · 18 employees · cardiolrx.com